Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic vaccines

A novel approach to therapeutic vaccines

AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.

More about AMAL

First-in-class immunisation technology

KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.

More about KISIMA®

Transforming the prospects of cancer patients

We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.

More about portfolio

Latest

News

More news

Events

  • SITC 2023

    November 1-5, 2023 / San Diego / USA

    Matteo Rossi, Head of in vivo Research, presenting

  • mRNA Cancer Vaccines Summit 2023

    October 10-12, 2023 / Boston / USA

    Marie-Laure Santiago-Raber, Senior Director Non-Clinical Development, attending

  • CICON 2023

    September 20-23, 2023 / Milano / Italy

    Elodie Belnoue, Senior Director Translational Research, presenting

More events

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL:

OK